Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05148546
Title Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications

clear cell renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Nivolumab + Relatlimab

Age Groups: senior | adult
Covered Countries


No variant requirements are available.